OPKO Health (OPK) Corporate presentation summary

Therapeutics pipeline and proprietary technologies

• Advancing a robust pipeline with five clinical-stage and five pre-IND assets, including multispecific antibodies and nanoparticle vaccines targeting oncology, immunology, and viral diseases.

• ModeX platforms validated through partnerships and clinical-stage programs, offering greater specificity and broad applications.

• Lead programs include EBV nanoparticle vaccine, multispecific immune rejuvenators, and long-acting biologics for metabolic and autoimmune disorders.

Strategic partnerships and business development

• Collaborations with Merck, BARDA, Regeneron, Pfizer, and Entera Bio provide up to $1B in milestone payments and royalties.

• Pfizer partnership for NGENLA enables global commercialization and significant profit share.

• Regeneron partnership leverages MSTAR platform for multispecific antibody discovery, with Regeneron funding all R&D and commercial activities.

Pharmaceutical and diagnostics business performance

• Specialty pharmaceuticals, including Rayaldee, show steady sales growth and positive cash flow, supporting R&D investments.

• BioReference Health streamlined through asset divestitures, generating up to $462.5M in cash and focusing on core clinical testing in NY/NJ.

• 4Kscore Test positioned for increased utilization and market share in diagnostics.